BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab. 2001;86:1306-1312. [PMID: 11238525 DOI: 10.1210/jc.86.3.1306] [Cited by in Crossref: 86] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Yatagai T, Nakamura T, Nagasaka S, Kusaka I, Ishikawa S, Yoshitaka A, Ishibashi S. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. Diabetes Research and Clinical Practice 2004;63:19-26. [DOI: 10.1016/j.diabres.2003.08.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
2 Takeshita Y, Takamura T, Hamaguchi E, Shimizu A, Ota T, Sakurai M, Kaneko S. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line. Metabolism 2006;55:1464-72. [PMID: 17046548 DOI: 10.1016/j.metabol.2006.06.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
3 Gumieniczek A, Hopkała H, Roliński J, Bojarska-junak A. Antioxidative and anti-inflammatory effects of repaglinide in plasma of diabetic animals. Pharmacological Research 2005;52:162-6. [DOI: 10.1016/j.phrs.2005.02.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
4 Sarayba MA, Li L, Tungsiripat T, Liu NH, Sweet PM, Patel AJ, Osann KE, Chittiboyina A, Benson SC, Pershadsingh HA, Chuck RS. Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand. Exp Eye Res 2005;80:435-42. [PMID: 15721625 DOI: 10.1016/j.exer.2004.10.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
5 Bhatt BA, O’doherty RM. Chapter 14 Insulin resistance, inflammation, and the IKK/IκB/NF-κB pathway. New Transcription Factors and their Role in Diabetes and its Therapy. Elsevier; 2006. pp. 279-321. [DOI: 10.1016/s1569-2566(06)05014-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
6 Goldberg RB. Thiazolidinediones and vascular damage: . Current Opinion in Endocrinology, Diabetes and Obesity 2007;14:108-15. [DOI: 10.1097/med.0b013e328054c655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Dandona P, Aljada A, O'donnell A, Dhindsa S, Garg R. Insulin Is an Anti-inflammatory and Anti-atherosclerotic Hormone. Metabolic Syndrome and Related Disorders 2004;2:137-42. [DOI: 10.1089/met.2004.2.137] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
8 Glueck CJ, Sieve L, Zhu B, Wang P. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 2006;55:345-52. [DOI: 10.1016/j.metabol.2005.09.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
9 Sutherland JP, McKinley B, Eckel RH. The metabolic syndrome and inflammation. Metab Syndr Relat Disord. 2004;2:82-104. [PMID: 18370640 DOI: 10.1089/met.2004.2.82] [Cited by in Crossref: 121] [Cited by in F6Publishing: 122] [Article Influence: 12.1] [Reference Citation Analysis]
10 Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome. Metabolic Syndrome and Related Disorders 2005;3:147-73. [DOI: 10.1089/met.2005.3.147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
11 Dandona P, Aljada A, Chaudhuri A, Mohanty P, Rajesh G. A novel view of metabolic syndrome. Metab Syndr Relat Disord 2004;2:2-8. [PMID: 18370671 DOI: 10.1089/met.2004.2.2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
12 Krebs M, Roden M. Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature. Diabetes Obes Metab 2005;7:621-32. [DOI: 10.1111/j.1463-1326.2004.00439.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 69] [Article Influence: 5.0] [Reference Citation Analysis]
13 Nesto R. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med. 2004;21:810-817. [PMID: 15270782 DOI: 10.1111/j.1464-5491.2004.01296.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 4.4] [Reference Citation Analysis]
14 Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. Journal of Diabetes and its Complications 2002;16:401-15. [DOI: 10.1016/s1056-8727(02)00202-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
15 Hamaguchi E, Takamura T, Shimizu A, Nagai Y. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J Pharmacol Exp Ther 2003;307:987-94. [PMID: 14534369 DOI: 10.1124/jpet.103.054346] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 3.3] [Reference Citation Analysis]
16 Tian YF, He CT, Chen YT, Hsieh PS. Lipoic acid suppresses portal endotoxemia-induced steatohepatitis and pancreatic inflammation in rats. World J Gastroenterol 2013; 19(18): 2761-2771 [PMID: 23687413 DOI: 10.3748/wjg.v19.i18.2761] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
17 Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab. 2007;9:218-232. [PMID: 17391148 DOI: 10.1111/j.1463-1326.2006.00594.x] [Cited by in Crossref: 122] [Cited by in F6Publishing: 102] [Article Influence: 8.1] [Reference Citation Analysis]
18 Oishi K, Ohkura N, Wakabayashi M, Shirai H, Sato K, Matsuda J, Atsumi G, Ishida N. CLOCK is involved in obesity-induced disordered fibrinolysis in ob/ob mice by regulating PAI-1 gene expression. J Thromb Haemost 2006;4:1774-80. [DOI: 10.1111/j.1538-7836.2006.02032.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 4.4] [Reference Citation Analysis]
19 Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care. 2002;5:561-568. [PMID: 12172481 DOI: 10.1097/00075197-200209000-00016] [Cited by in Crossref: 274] [Cited by in F6Publishing: 255] [Article Influence: 13.7] [Reference Citation Analysis]
20 Greenberg AS. The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones. Journal of Diabetes and its Complications 2003;17:218-28. [DOI: 10.1016/s1056-8727(03)00002-3] [Cited by in Crossref: 17] [Article Influence: 0.9] [Reference Citation Analysis]
21 Rafehi H, Ververis K, Karagiannis TC. Controversies surrounding the clinical potential of cinnamon for the management of diabetes. Diabetes Obes Metab 2012;14:493-9. [PMID: 22093965 DOI: 10.1111/j.1463-1326.2011.01538.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
22 Zingarelli B, Sheehan M, Hake PW, O’connor M, Denenberg A, Cook JA. Peroxisome Proliferator Activator Receptor-γ Ligands, 15-Deoxy-Δ 12,14 -Prostaglandin J 2 and Ciglitazone, Reduce Systemic Inflammation in Polymicrobial Sepsis by Modulation of Signal Transduction Pathways. J Immunol 2003;171:6827-37. [DOI: 10.4049/jimmunol.171.12.6827] [Cited by in Crossref: 149] [Cited by in F6Publishing: 150] [Article Influence: 7.8] [Reference Citation Analysis]
23 Albertini J, Mcmorn SO, Chen H, Mather RA, Valensi P. Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. Atherosclerosis 2007;195:e159-66. [DOI: 10.1016/j.atherosclerosis.2007.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
24 Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169-2180. [PMID: 17498510 DOI: 10.1053/j.gastro.2007.03.059] [Cited by in Crossref: 1060] [Cited by in F6Publishing: 1008] [Article Influence: 70.7] [Reference Citation Analysis]
25 El-atat FA, Nicasio J, Clark LT, Mcfarlane SI. An overview of the beneficial cardiovascular effects of thiazolidinediones. Therapy 2005;2:113-9. [DOI: 10.2217/14750708.2.1.113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
26 Aljada A, Mohanty P, Dandona P. Lipids, carbohydrates, and heart disease. Metab Syndr Relat Disord 2003;1:185-8. [PMID: 18370661 DOI: 10.1089/154041903322716651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
27 Dandona P. Insulin resistance and endothelial dysfunction in atherosclerosis: implications and interventions. Diabetes Technol Ther. 2002;4:809-815. [PMID: 12614487 DOI: 10.1089/152091502321118829] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
28 Dandona P, Chaudhuri A, Aljada A. Endothelial dysfunction and hypertension in diabetes mellitus. Med Clin North Am 2004;88:911-31, x-xi. [PMID: 15308385 DOI: 10.1016/j.mcna.2004.04.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
29 Zebrack JS, Anderson JL. Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice. Prog Cardiovasc Nurs 2002;17:174-85. [PMID: 12417833 DOI: 10.1111/j.0889-7204.2002.1118.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
30 Jellinger PS. Metabolic consequences of hyperglycemia and insulin resistance. Insulin 2009;4:2-14. [DOI: 10.1016/s1557-0843(09)80003-1] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
31 Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007;261:293-305. [DOI: 10.1111/j.1365-2796.2007.01767.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
32 Cheng HM, Li CC, Chen CY, Lo HY, Cheng WY, Lee CH, Yang SZ, Wu SL, Hsiang CY, Ho TY. Application of bioactivity database of Chinese herbal medicine on the therapeutic prediction, drug development, and safety evaluation. J Ethnopharmacol 2010;132:429-37. [PMID: 20713146 DOI: 10.1016/j.jep.2010.08.022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
33 Dandona P. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. Mayo Clin Proc 2008;83:333-42. [PMID: 18316001 DOI: 10.4065/83.3.333] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
34 Jawa AA, Fonseca VA. Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes. Cardiology Clinics 2005;23:119-38. [DOI: 10.1016/j.ccl.2004.06.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
35 Kajbaf F, Mojtahedzadeh M, Abdollahi M. Mechanisms underlying stress-induced hyperglycemia in critically ill patients. Therapy 2007;4:97-106. [DOI: 10.2217/14750708.4.1.97] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
36 Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004;6:280-5. [DOI: 10.1111/j.1462-8902.2004.0348.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
37 Dandona P, Aljada A. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents. Journal of Diabetes and its Complications 2004;18:91-102. [DOI: 10.1016/s1056-8727(02)00259-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
38 Dandona P, Dhindsa S, Aljada A, Garg R. Insulin as an anti-inflammatory and antiatherosclerotic hormone. Clinical Cornerstone 2003;5:S13-20. [DOI: 10.1016/s1098-3597(03)90062-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
39 Tripathy D, Dhindsa S, Garg R, Khaishagi A, Syed T, Dandona P. Hypogonadotropic hypogonadism in erectile dysfunction associated with type 2 diabetes mellitus: a common defect? Metab Syndr Relat Disord 2003;1:75-80. [PMID: 18370627 DOI: 10.1089/154041903321648270] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
40 Dandona P, Ghanim H, Chaudhuri A, Mohanty P. Thiazolidinediones—improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. Journal of Diabetes and its Complications 2008;22:62-75. [DOI: 10.1016/j.jdiacomp.2006.10.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
41 Braun J, Targan SR. Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of inflammatory bowel disease. Adv Exp Med Biol 2006;579:209-18. [PMID: 16620020 DOI: 10.1007/0-387-33778-4_13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
42 Barzilaym JI, Freedland ES. Inflammation and its relationship to insulin resistance, type 2 diabetes mellitus, and endothelial dysfunction. Metab Syndr Relat Disord 2003;1:55-67. [PMID: 18370625 DOI: 10.1089/154041903321648252] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
43 Christon R, Drouin O, Marette A. Redox Modulation of Insulin Signaling and Endothelial Function. Antioxidants & Redox Signaling 2005;7:1062-70. [DOI: 10.1089/ars.2005.7.1062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
44 Aljada A. Endothelium, inflammation, and diabetes. Metab Syndr Relat Disord. 2003;1:3-21. [PMID: 18370622 DOI: 10.1089/154041903321648225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
45 Woster AP, Combs CK. Differential ability of a thiazolidinedione PPARgamma agonist to attenuate cytokine secretion in primary microglia and macrophage-like cells. J Neurochem 2007;103:67-76. [PMID: 17573821 DOI: 10.1111/j.1471-4159.2007.04706.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
46 Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci. 2006;1084:89-117. [PMID: 17151295 DOI: 10.1196/annals.1372.039] [Cited by in Crossref: 188] [Cited by in F6Publishing: 180] [Article Influence: 12.5] [Reference Citation Analysis]
47 Bragt MC, Popeijus HE. Peroxisome proliferator-activated receptors and the metabolic syndrome. Physiol Behav 2008;94:187-97. [PMID: 18191967 DOI: 10.1016/j.physbeh.2007.11.053] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
48 Vinik A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 2007;29:1236-53. [PMID: 18036387 DOI: 10.1016/j.clinthera.2007.07.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
49 Dandona P, Dhindsa S, Aljada A, Chaudhuri A. Classical Anti-oxidants (Scavengers) versus Biological Anti-oxidants (Suppressors of ROS Generation): ANovel Way to Explain the Anti-oxidant Paradox. Metab Syndr Relat Disord 2004;2:155-9. [PMID: 18370680 DOI: 10.1089/met.2004.2.155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
50 Vasudevan AR, Balasubramanyam A. Thiazolidinediones: A Review of Their Mechanisms of Insulin Sensitization, Therapeutic Potential, Clinical Efficacy, and Tolerability. Diabetes Technology & Therapeutics 2004;6:850-63. [DOI: 10.1089/dia.2004.6.850] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 3.6] [Reference Citation Analysis]
51 Bertrand OF, Poirier P, Rodés-cabau J, Rinfret S, Title LM, Dzavik V, Natarajan M, Angel J, Batalla N, Alméras N, Costerousse O, De Larochellière R, Roy L, Després J. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial. Atherosclerosis 2010;211:565-73. [DOI: 10.1016/j.atherosclerosis.2010.06.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
52 van Eeden SF, Sin DD. Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease. Respiration 2008;75:224-38. [PMID: 18042978 DOI: 10.1159/000111820] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
53 Hsieh MS, Hung PS, Hsieh VC, Liao SH, How CK. Association between thiazolidinedione use and rheumatoid arthritis risk in patients with type II diabetes, a population-based, case-control study. Int J Clin Pract 2021;75:e13804. [PMID: 33124165 DOI: 10.1111/ijcp.13804] [Reference Citation Analysis]